Tadaaki Nishikawa

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 76 publications

Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer.

Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer.

Journal: Future oncology (London, England)

Published: April 07, 2026

Vaginal high-intensity focused ultrasound in women with genitourinary syndrome of menopause: a prospective exploratory study.

Vaginal high-intensity focused ultrasound in women with genitourinary syndrome of menopause: a prospective exploratory study.

Journal: Sexual medicine

Published: March 17, 2026

Optimal adjuvant strategy in intermediate-risk cervical cancer: a systematic review and meta-analysis.

Optimal adjuvant strategy in intermediate-risk cervical cancer: a systematic review and meta-analysis.

Journal: International journal of clinical oncology

Published: January 20, 2026

Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial.

Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial.

Journal: Gynecologic oncology

Published: November 28, 2025

Clinical, immunological, and genomic findings of atezolizumab in advanced alveolar soft part sarcoma: A phase II trial (ALBERT trial/NCCH1907).

Clinical, immunological, and genomic findings of atezolizumab in advanced alveolar soft part sarcoma: A phase II trial (ALBERT trial/NCCH1907).

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 31, 2025

Establishing a comprehensive panel of patient-derived xenograft models for high-grade endometrial carcinoma: molecular subtypes, genetic alterations, and therapeutic target profiling.

Establishing a comprehensive panel of patient-derived xenograft models for high-grade endometrial carcinoma: molecular subtypes, genetic alterations, and therapeutic target profiling.

Journal: Neoplasia (New York, N.Y.)

Published: February 03, 2025

Development of Antibody-Drug Conjugates for Malignancies of the Uterine Corpus: A Review.

Development of Antibody-Drug Conjugates for Malignancies of the Uterine Corpus: A Review.

Journal: Cells

Published: January 21, 2025

Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models.

Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models.

Journal: Molecular cancer therapeutics

Published: January 14, 2025

Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial.

Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial.

Journal: Journal of gynecologic oncology

Published: November 27, 2024

Efficacy of Eribulin Monotherapy in Patients With Unresectable and/or Metastatic Adenoid Cystic Carcinoma Receiving Platinum-Based Therapy.

Efficacy of Eribulin Monotherapy in Patients With Unresectable and/or Metastatic Adenoid Cystic Carcinoma Receiving Platinum-Based Therapy.

Journal: Head & neck

Published: September 13, 2024

The efficacy and safety of lenvatinib plus pembrolizumab therapy in patients with uterine carcinosarcoma.

The efficacy and safety of lenvatinib plus pembrolizumab therapy in patients with uterine carcinosarcoma.

Journal: Gynecologic oncology reports

Published: June 27, 2024

Folate Receptor Alpha Expression and the Tumor Immune Microenvironment in Patients with Cervical Cancer.

Folate Receptor Alpha Expression and the Tumor Immune Microenvironment in Patients with Cervical Cancer.

Journal: International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists

Published: June 24, 2024

Showing 1-12 of 76

Last Updated: 09/26/2026